Hematology

The overall survival of patients with chronic lymphocytic leukemia (CLL) has improved significantly over the years; however, the clinical…

Prof. Alexander Röth (Chair), Prof. Wilma Barcellini, Prof. Josephine Vos and Prof. Bernd Jilma, will discuss about the evolving treatment paradigm in cold agglutinin disease (CAD): challenges and opportunities for optimal management.

Not able to attend the Expert Roundtable Discussion in Paris? Access the on-demand webcast here. This interactive event features expert perspectives on current and emerging uses of BTK inhibitors for CLL and MCL. Topics include:

Latest updates in Advanced Systemic Mastocytosis from EHA 2022. Targeting systemic mastocytosis. Update in Haematology session EHA 2022, Prof. Olivier Hermine introduces the  session on overcoming the challenges in diagnosis and management of advanced systemic macrocytosis.

*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

Insight beyond Phase 3: Does real-world evidence impact how we treat high-risk AML…

Dr Simona Soverini discusses early molecular response, next-generation sequencing, and the impact of tyrosine kinase inhibitor-resistant mutations in…

Delve into the venue for this year’s European Hematology Association (EHA) Congress.